Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press115410.17650/1726-9776-2006-2-4-53-58DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. TESTICULAR CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак яичкаTreatment of early (I, IIA/B) stages of germinomas of the testisЛечение ранних (I, IIA/B) стадий герминогенных опухолей яичкаTryakinA. A.ТрякинА. А.
Russian Federation

Department of Clinical Pharmacology and Chemotherapy

BulanovA. A.БулановА. А.
Russian Federation

Department of Clinical Pharmacology and Chemotherapy

TyulyandinS. A.ТюляндинС. А.
Russian Federation

Department of Clinical Pharmacology and Chemotherapy

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина РАМН301220062453581702202017022020https://oncourology.abvpress.ru/oncur/article/view/1154

Germinomas of the testis are most commonly presented in early (I-II) stages. In Stage T, choice of adjuvant therapy is based on the type of a tumor, the presence of risk factors, and a patient’s wishes. Seminoma requires monitoring, radiotherapy (20 Gy paraaortically) or chemotherapy (a course pf carboplatin therapy), non-seminomic testicular tumors call for monitoring, nerve-preserving retroperitoneal lymphadenectomy (NPRLAE) or chemotherapy (2 courses of ВЕР). All treatment modalities ensure recovery in above 95% of patients. In Stage II, the similar results can be achieved by radiotherapy or chemotherapy (3 courses of ВЕР) in patients with seminoma, by NPRLAE or chemotherapy (3 courses of ВЕР) in patients with non-seminomic tumors of the testis. The equal efficiency of all approaches generates a need for discussing all possible treatment modalities with the patient, by taking into account toxicity and convenience.

.

1. Аксель Е.М., Трапезников Н.Н. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1999 г. М., 2001.Аксель Е.М., Трапезников Н.Н. Заболеваемость злокачественными новообразованиями и смертность от них населения стран СНГ в 1999 г. М., 2001.2. Альмяшев А.З., Кулаев М.Т., Бегоулов И.В. и др. Клиника, диагностика и лечение злокачественных опухолей яичка. Методические указания для врачей и студентов. Саранск, 2001.Альмяшев А.З., Кулаев М.Т., Бегоулов И.В. и др. Клиника, диагностика и лечение злокачественных опухолей яичка. Методические указания для врачей и студентов. Саранск, 2001.3. Мерабишвили В.М. Выживаемость онкологических больных. СПб., ООО «Фирма Коста», 2006.Мерабишвили В.М. Выживаемость онкологических больных. СПб., ООО «Фирма Коста», 2006.4. Heidenreich A., Weissbach L., Höltl W. et al. German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166:2161–5.Heidenreich A., Weissbach L., Höltl W. et al. German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001;166:2161–5.5. Warde P., Specht L., Horwich A. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448–52.Warde P., Specht L., Horwich A. et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448–52.6. Travis L.B., Curtis R.E., Storm H. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.Travis L.B., Curtis R.E., Storm H. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.7. Aparicio J., Garcia del Muro X., Maroto P. et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867–72.Aparicio J., Garcia del Muro X., Maroto P. et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 2003;14(6):867–72.8. Oliver R.T., Mason M., von der Masse H. et al. on behalf of the MRC Testis Tumour Group and the EORTC GU Group. A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Proc Am Soc Clin Oncol 2004;23, 385; Abstr. 4517.Oliver R.T., Mason M., von der Masse H. et al. on behalf of the MRC Testis Tumour Group and the EORTC GU Group. A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Proc Am Soc Clin Oncol 2004;23, 385; Abstr. 4517.9. Calvert A.H., Newell D.R., Gumbrell L.A. et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.Calvert A.H., Newell D.R., Gumbrell L.A. et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–56.10. Spermon J.R., Roeleveld T.A., van der Poel H.G. et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 2002;59:923–9.Spermon J.R., Roeleveld T.A., van der Poel H.G. et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 2002;59:923–9.11. Read G., Stenning S.P., Cullem M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762–8.Read G., Stenning S.P., Cullem M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762–8.12. Albers P., Siener R., Kliesch S. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 2003;21:1505–12.Albers P., Siener R., Kliesch S. et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group trial. J Clin Oncol 2003;21:1505–12.13. Klepp O., Dahl O., Flodgren P. et al. Risk-adapted treatment of clinical stage I non-seminoma testis cancer. Eur J Cancer 1997;33:1038–44.Klepp O., Dahl O., Flodgren P. et al. Risk-adapted treatment of clinical stage I non-seminoma testis cancer. Eur J Cancer 1997;33:1038–44.14. Read G., Stenning S.P., Cullen M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762–8.Read G., Stenning S.P., Cullen M.H. et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:1762–8.15. Hartmann J.T., Albrecht C., Schmoll H.J. et al. Long term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999;80:801–7.Hartmann J.T., Albrecht C., Schmoll H.J. et al. Long term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999;80:801–7.16. Travis L.B., Curtis R.E., Storm H. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.Travis L.B., Curtis R.E., Storm H. et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.17. Link R.E., Allaf M.E., Pili R., Kavoussi L.R. Modeling the Cost of Management Options for Stage I Nonseminomatous Germ Cell Tumors: A Decision Tree Analysis. J Clin Oncol 2005,23:5762–73.Link R.E., Allaf M.E., Pili R., Kavoussi L.R. Modeling the Cost of Management Options for Stage I Nonseminomatous Germ Cell Tumors: A Decision Tree Analysis. J Clin Oncol 2005,23:5762–73.18. Classen J., Schmidberger H., Meisner C. et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101–6.Classen J., Schmidberger H., Meisner C. et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:1101–6.19. Fossa S.D., Horwich A. Current status of chemotherapy in advanced seminoma. Eur J Cancer 1997;33(2):181–3.Fossa S.D., Horwich A. Current status of chemotherapy in advanced seminoma. Eur J Cancer 1997;33(2):181–3.20. Albers P., Weinknecht S., Krege S. et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors – results of a prospective multicenter trial of the GTCSG. J Urol 2002;167(Suppl):172. Abstr. 690.Albers P., Weinknecht S., Krege S. et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors – results of a prospective multicenter trial of the GTCSG. J Urol 2002;167(Suppl):172. Abstr. 690.21. De Santis M., Bokemeyer C., Becherer A. et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740–4.De Santis M., Bokemeyer C., Becherer A. et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol 2001;19:3740–4.22. Stephenson A., Bosl G., Bajorin D. et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174:557–60.Stephenson A., Bosl G., Bajorin D. et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005;174:557–60.23. Weissbach L., Bussar-Maatz R., Flechtner H. et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582–94.Weissbach L., Bussar-Maatz R., Flechtner H. et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582–94.24. Fizazi K., Tjulandin S., Salvioni R. et al. Viable malignant cells after primary chemotherapy for disseminated nonseminatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an international study. J Clin Oncol 2001;19:2647–7.Fizazi K., Tjulandin S., Salvioni R. et al. Viable malignant cells after primary chemotherapy for disseminated nonseminatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an international study. J Clin Oncol 2001;19:2647–7.